Last summer, something monumental happened. One of Uncuffed's founding producers, Greg Eskridge, came home after more than 30 years in prison. In this episode we’ll bring you back to that emotional day last summer when he walked out of the San Quentin gates, free at last. Our work in prisons is supported by the California Arts Council, the California Department of Corrections and Rehabilitation, independent foundations, and donations from listeners like you. Learn more, sign up for Uncuffed news, and support the program at www.weareuncuffed.org Follow us @WeAreUncuffed on Instagram and Facebook Transcripts are available within a week of the episode coming out at www.kalw.org/podcast/uncuffed…
Player FM - Internet Radio Done Right
Checked 16d ago
تمت الإضافة منذ fifty-one أسبوع
المحتوى المقدم من Healio. يتم تحميل جميع محتويات البودكاست بما في ذلك الحلقات والرسومات وأوصاف البودكاست وتقديمها مباشرة بواسطة Healio أو شريك منصة البودكاست الخاص بهم. إذا كنت تعتقد أن شخصًا ما يستخدم عملك المحمي بحقوق الطبع والنشر دون إذنك، فيمكنك اتباع العملية الموضحة هنا https://ar.player.fm/legal.
Player FM - تطبيق بودكاست
انتقل إلى وضع عدم الاتصال باستخدام تطبيق Player FM !
انتقل إلى وضع عدم الاتصال باستخدام تطبيق Player FM !
))
Daily Deals
DME/Retina Edition: Top Headlines for Week of June 3, 2024
Manage episode 422229053 series 3560281
المحتوى المقدم من Healio. يتم تحميل جميع محتويات البودكاست بما في ذلك الحلقات والرسومات وأوصاف البودكاست وتقديمها مباشرة بواسطة Healio أو شريك منصة البودكاست الخاص بهم. إذا كنت تعتقد أن شخصًا ما يستخدم عملك المحمي بحقوق الطبع والنشر دون إذنك، فيمكنك اتباع العملية الموضحة هنا https://ar.player.fm/legal.
In this edition, AI model helps predict anti-VEGF response in DME, Merck to acquire EyeBio and more. Read the full coverage here:
VIDEO: AI model helps predict anti-VEGF response in diabetic macular edema
VIDEO: IOP remains stable up to 48 weeks with aflibercept 8 mg for DME
Phase 2 study of potential DME oral therapy meets primary endpoints
FDA approves aflibercept biosimilars Yesafili, Opuviz
References:
Barakat MR. Intraocular pressure outcomes with intravitreal injection of aflibercept 8 mg and 2 mg in patients with diabetic macular edema through week 48 of the phase 2/3 PHOTON trial. Presented at: Association for Research in Vision and Ophthalmology meeting; May 5-9, 2024; Seattle.
Luvisi J. Using a convolutional neural network to predict response of diabetic macular edema to intravitreal anti-vascular endothelial growth factor. Presented at: Kiawah Eye; May 30-June 1, 2024; Kiawah Island, South Carolina.
122 حلقات
مشاركةManage episode 422229053 series 3560281
المحتوى المقدم من Healio. يتم تحميل جميع محتويات البودكاست بما في ذلك الحلقات والرسومات وأوصاف البودكاست وتقديمها مباشرة بواسطة Healio أو شريك منصة البودكاست الخاص بهم. إذا كنت تعتقد أن شخصًا ما يستخدم عملك المحمي بحقوق الطبع والنشر دون إذنك، فيمكنك اتباع العملية الموضحة هنا https://ar.player.fm/legal.
In this edition, AI model helps predict anti-VEGF response in DME, Merck to acquire EyeBio and more. Read the full coverage here:
VIDEO: AI model helps predict anti-VEGF response in diabetic macular edema
VIDEO: IOP remains stable up to 48 weeks with aflibercept 8 mg for DME
Phase 2 study of potential DME oral therapy meets primary endpoints
FDA approves aflibercept biosimilars Yesafili, Opuviz
References:
Barakat MR. Intraocular pressure outcomes with intravitreal injection of aflibercept 8 mg and 2 mg in patients with diabetic macular edema through week 48 of the phase 2/3 PHOTON trial. Presented at: Association for Research in Vision and Ophthalmology meeting; May 5-9, 2024; Seattle.
Luvisi J. Using a convolutional neural network to predict response of diabetic macular edema to intravitreal anti-vascular endothelial growth factor. Presented at: Kiawah Eye; May 30-June 1, 2024; Kiawah Island, South Carolina.
122 حلقات
كل الحلقات
×
1 Lung Cancer Edition: Top Headlines for Week of February 17, 2025 13:36
13:36 
التشغيل لاحقا 
التشغيل لاحقا 
قوائم 
إعجاب 
احب13:36
التشغيل لاحقا التشغيل لاحقا قوائم إعجاب احبIn this edition, robotic-assisted bronchoscopy a ‘game changer’, global mortality related to tobacco drops, particulate matter rises and more. Read the full coverage here: Robotic-assisted bronchoscopy a ‘game changer’ in early diagnosis of lung cancer Global lung cancer mortality related to tobacco drops, particulate matter rises in 2019 Osimertinib linked to more therapy-related cardiac events than other TKIs for NSCLC Survival better with lobectomy vs. wedge resection in early stage lung cancer Zenocutuzumab exhibits efficacy in NRG1 fusion-positive cancers References: Expert Submission Jani CT, et al. eClinicalMedicine. 2025;doi:10.1016/j.eclinm.2024.103033. Lin CY, et al. JAMA Netw Open . 2024;doi:10.1001/jamanetworkopen.2024.48364. Schram AM, et al. N Engl J Med. 2025;doi:10.1056/NEJMoa2405008 . Seder C. Anatomic lung resection is associated with improved survival compared with wedge resection for stage IA non-small cell lung cancer. Presented at: 2025 Society of Thoracic Surgeons Annual Meeting; Jan. 24-26; Los Angeles.…
1 Lung Cancer Edition: Top Headlines for Week of January 20, 2025 11:23
11:23 التشغيل لاحقا التشغيل لاحقا قوائم إعجاب احب11:23
التشغيل لاحقا التشغيل لاحقا قوائم إعجاب احبIn this edition, combination extends survival vs. standard first-line therapy, integrated care for smoking cessation during lung cancer screening and more. Read the full coverage here: Combination extends survival vs. standard first-line therapy for advanced lung cancer Integrated care ‘best treatment option’ for smoking cessation during lung cancer screening FDA proposes cap on nicotine levels in cigarettes Global lifetime risk for lung cancer in 2022 differs by human development index, sex FDA grants priority review to oral non-small cell lung cancer drug References: Cinciripini P, et al. JAMA Intern Med . 2024;doi:10.1001/jamainternmed.2024.7288. Li M, et al. Chin Med J (Engl). 2024;doi:10.1097/CM9.0000000000003368. Press Release Press Release Press Release…
1 Lung Cancer Edition: Top Headlines for Week of December 16, 2024 13:25
13:25 التشغيل لاحقا التشغيل لاحقا قوائم إعجاب احب13:25
التشغيل لاحقا التشغيل لاحقا قوائم إعجاب احبIn this edition, we bring you Healio’s top lung cancer headlines in 2024. Read the full coverage here: California doctor with lung cancer receives first-of-its-kind lung-liver transplant ‘We were shocked’: Vaping considerably increases lung cancer risk among people who smoke FDA places hold on trial of cell therapy for lung cancer after patient death Findings highlight ‘desperate need’ to improve end-of-life cancer treatment ‘We have the technology’: Telehealth increases access to palliative care for cancer References: Canavan ME, et al. JAMA Oncol . 2024;doi:10.1001/jamaoncol.2024.1129. Greer JA, et al. Abstract LBA3. Presented at: ASCO Annual Meeting; May 31-June 4, 2024: Chicago. Healio Interviews Press Release Press Release…
1 Lung Cancer Edition: Top Headlines for Week of November 11, 2024 10:57
10:57 التشغيل لاحقا التشغيل لاحقا قوائم إعجاب احب10:57
التشغيل لاحقا التشغيل لاحقا قوائم إعجاب احبIn this edition, single-fraction SBRT outcomes for central lung tumors, adjuvant durvalumab extends survival in limited-stage small cell lung cancer and more. Read the full coverage here: Single-fraction SBRT confers ‘surprisingly excellent’ outcomes for central lung tumors Adjuvant durvalumab extends survival in limited-stage small cell lung cancer Depression among people with head and neck cancers likely underreported, undertreated FDA approves tumor treating fields as part of combination therapy for advanced lung cancer First-line maintenance regimen improves OS, PFS in extensive-stage small cell lung cancer References: Cheng Y, et al. Abstract LBA81. Presented at: European Society for Medical Oncology Congress; Sept. 13-17, 2024; Barcelona, Spain. Malik NK, et al. Abstract 285. Presented at: ASTRO Annual Meeting; Sept. 29-Oct. 2, 2024; Washington, D.C. Martinez MC, et al. JAMA Otolaryngol Head Neck Surg . 2024;doi:10.1001/jamaoto.2024.3233 . Press Release Press Release…
1 Lung Cancer Edition: Top Headlines for Week of October 14, 2024 10:45
10:45 التشغيل لاحقا التشغيل لاحقا قوائم إعجاب احب10:45
التشغيل لاحقا التشغيل لاحقا قوائم إعجاب احبIn this edition, FDA approves Rybrevant for advanced lung cancer, screening orders in eligible patients higher with digital health program and more. Read the full coverage here: FDA approves Rybrevant for advanced lung cancer Lung cancer screening orders in eligible patients higher with digital health program FDA approves Opdivo regimen for resectable NSCLC Study quantifies survival benefit of immunotherapy in metastatic NSCLC FDA expands osimertinib approval for advanced non-small cell lung cancer References: Miller DP, et al. A direct-to-patient digital health program increases lung cancer screening: A pragmatic randomized controlled trial of mPATH-Lung. Presented at: CHEST Annual Meeting; Oct. 6-9, 2024; Boston . Press Release Press Release Press Release Ward Y, et al. Cancer. 2024;doi:10.1002/cncr.35476 .…
1 Rheumatology/Psoriatic Arthritis Edition: Top Headlines for Week of September 23, 2024 11:48
11:48 التشغيل لاحقا التشغيل لاحقا قوائم إعجاب احب11:48
التشغيل لاحقا التشغيل لاحقا قوائم إعجاب احبIn this edition, blue-collar workers more likely to miss work or quit due to psoriatic arthritis, infliximab biosimilar increase after release of a third option and more. Read the full coverage here: Blue-collar workers more likely to miss work, quit due to psoriatic arthritis Infliximab biosimilar uptake rapidly increased only after release of a third option National Psoriasis Foundation to honor leaders at 2025 Commit to Cure Gala Safety checklist compiles clinically important DMARD warnings in one place Guselkumab demonstrates long-term efficacy, safety in psoriasis References: Colla N, et al. Clin Rheumatol. 2024;doi:10.1007/s10067-024-07077-1. Gargiulo L, et al. J Drugs Dermatol . 2024;doi:10.36849/JDD.7486R1. Press Release Roberts ET, et al. Arthritis Rheumatol. 2024;doi:10.1002/art.42963. Skaarup L, et al. Drug Saf. 2024;doi:10.1007/s40264-024-01461-1.…
1 Lung Cancer Edition: Top Headlines for Week of September 16, 2024 13:55
13:55 التشغيل لاحقا التشغيل لاحقا قوائم إعجاب احب13:55
التشغيل لاحقا التشغيل لاحقا قوائم إعجاب احبIn this edition, FDA approves first subcutaneous anti-PD-L1 cancer immunotherapy, ivonescimab ‘may be a new standard’ and more. Read the full coverage here: FDA approves first subcutaneous anti-PD-L1 cancer immunotherapy Ivonescimab extends PFS vs. pembrolizumab in advanced NSCLC, may be ‘a new standard’ Perioperative nivolumab improves outcomes in resectable NSCLC Despite progress, barriers to lung cancer biomarker testing persist Atezolizumab regimen ‘merits further study’ for unresectable NSCLC References: Forde PM, et al. Abstract 3589. Presented at: IASLC World Conference on Lung Cancer; Sept. 7-10, 2024; San Diego. Press Release Ross HJ, et al. JAMA Oncol. 2024;doi:10.1001/jamaoncol.2024.1897. Smeltzer M, et al. Abstract 3000. Presented at: IASLC World Conference on Lung Cancer; Sept. 7-10, 2024; San Diego. Zhou C, et al. Abstract 2700. Presented at: IASLC World Conference on Lung Cancer; Sept. 7-10, 2024; San Diego.…
1 DME/Retina Edition: Top Headlines for Week of September 9, 2024 8:40
8:40 التشغيل لاحقا التشغيل لاحقا قوائم إعجاب احب8:40
التشغيل لاحقا التشغيل لاحقا قوائم إعجاب احبIn this edition, enrollment and dosing complete in phase 1 trial of AIV007, popular benchmarks in clinical practice guidelines and more. Read the full coverage here: Enrollment, dosing complete in phase 1 trial of AIV007 for AMD, diabetic macular edema OCT, visual acuity popular benchmarks in clinical practice guidelines for DME First patient dosed in phase 2 trial of EC-104 implant for diabetic macular edema OCS-01 eye drop for DME in second stage of phase 3 trial Q&A: Susvimo delivers immediate durability after implantation in wet AMD References: Crawford C. Update on OCS-01: A novel topical drop for DME in phase 3 trials. Presented at: Clinical Trials at the Summit; June 8, 2024; Park City, Utah. Healio Interviews McAllister M, et al. Assessing the strength of clinical practice guidelines for managing diabetic macular edema — A systematic literature review. Presented at: American Society of Retina Specialists annual meeting; July 17-20, 2024; Stockholm. Press Release Press Release…
1 Rheumatology/Psoriatic Arthritis Edition: Top Headlines for Week of August 19, 2024 11:18
11:18 التشغيل لاحقا التشغيل لاحقا قوائم إعجاب احب11:18
التشغيل لاحقا التشغيل لاحقا قوائم إعجاب احبIn this edition, drug discounts through Medicare price negotiations, opioid use has fallen 15% annually since 2014 and more. Read the full coverage here: Enbrel, Stelara to be discounted nearly 70% through Medicare price negotiations Opioid use has fallen 15% annually since 2014 in autoimmune rheumatic disease Inhibitor class PsO treatments exhibit similar efficacy in mitigating PsA risk S100 protein levels predict abatacept response in juvenile idiopathic arthritis Izokibep shows early promise in hidradenitis suppurativa References: Brunner HI, et al. Arthritis Res Ther. 2024;doi:10.1186/s13075-024-03347-0. Falasinnu T, et al. Lancet Rheumatol. 2024;doi:10.1016/S2665-9913(24)00120-6. Press Release Press Release Tsai SHL, et al. J Am Acad Dermatol . 2024;doi:10.1016/j.jaad.2024.07.1473 .…
1 Lung Cancer Edition: Top Headlines for Week of August 12, 2024 15:14
15:14 التشغيل لاحقا التشغيل لاحقا قوائم إعجاب احب15:14
التشغيل لاحقا التشغيل لاحقا قوائم إعجاب احبIn this edition, low education level raises follow-up risk in screening program, screening judgement strongly influenced by clinicians and more. Read the full coverage here: Low education level raises risk for loss to follow-up in lung cancer screening program Lung cancer screening judgement strongly influenced by clinicians Occupational benzene exposure heightens lung cancer likelihood Chemotherapy plus nintedanib has ‘promising’ efficacy in small cell lung cancer with IPF Blood biomarker identifying benign lung nodules performs well across subgroups References: Ikeda S, et al. Ann Am Thorac Soc. 2024;doi:10.1513/AnnalsATS.202311-941OC. Long KJ, et al. CHEST. 2023;doi:10.1016/j.chest.2023.06.037. Mugutso E, et al. Ann Am Thorac Soc. 2023;doi:10.1513/AnnalsATS.202304-348RL. Núñez ER, et al. Am J Respir Crit Care Med. 2024;doi:10.1164/rccm.202301-0155OC. Wan W, et al. Am J Respir Crit Care Med. 2024;doi:10.1164/rccm.202306-0942OC.…
1 DME/Retina Edition: Top Headlines for Week of August 5, 2024 11:23
11:23 التشغيل لاحقا التشغيل لاحقا قوائم إعجاب احب11:23
التشغيل لاحقا التشغيل لاحقا قوائم إعجاب احبIn this edition, sozinibercept combination therapy shows durability, comparable improvements with aflibercept and more. Read the full coverage here: Sozinibercept combination therapy shows durability in patients with DME, neovascular AMD VIDEO: Comparable improvements seen with aflibercept 8 mg vs. 2 mg in DME DPP-IV, SGLT2 and GLP-1 drugs do not increase risk for diabetic macular edema Eluminex doses first patient in phase 1b trial of EB-105 for diabetic macular edema VIDEO: Port delivery system maintains visual, anatomic improvements in DME at 2 years References: Awh C. Port delivery system with ranibizumab for continuous treatment of diabetic macular edema: First readout of the phase 3 Pagoda trial year 2 results. Presented at: American Society of Retina Specialists annual meeting; July 17-20, 2024; Stockholm. Do D. Outcomes of patients with DME and baseline BCVA of 20/50 or worse or 20/40 or better treated with aflibercept 8 mg and 2 mg in the phase 2/3 PHOTON trial. Presented at: American Society of Retina Specialists annual meeting; July 17-20, 2024; Stockholm. Phu A, et al. J Diabetes Complications. 2024;doi:10.1016/j.jdiacomp.2024.108808. Press Release Steinle NC. Durability of combination therapy of sozinibercept (OPT-302), an anti-VEGF-C/-D ‘trap’ with ranibizumab in nAMD or aflibercept in DME. Presented at: American Society of Retina Specialists annual meeting; July 17-20, 2024; Stockholm.…
1 Rheumatology/Psoriatic Arthritis Edition: Top Headlines for Week of July 22, 2024 11:11
11:11 التشغيل لاحقا التشغيل لاحقا قوائم إعجاب احب11:11
التشغيل لاحقا التشغيل لاحقا قوائم إعجاب احبIn this edition, guselkumab brings ‘stringent’ control through 2 years, SARDs outpatient visits result in opioid prescriptions and more. Read the full coverage here: Guselkumab brings active psoriatic arthritis into ‘stringent’ control through 2 years Nearly one-quarter of all SARDs outpatient visits in US result in opioid prescription FDA approves biosimilar Pyzchiva for all approved Stelara indications Tofacitinib effective for juvenile idiopathic arthritis through 4 years Bimekizumab results in rapid, sustained improvements to PsA patient reported outcomes References: Brunner HI, et al. Ann Rheum Dis. 2024;doi:10.1136/ard-2023-225094. Gossec L, et al. Rheumatology. 2024;doi:10.1093/rheumatology/keae277. Huang Y, et al. Arthritis Care Res. 2024;doi:10.1002/acr.25378. Press Release Ritchlin CT, et al. Clin Rheumatol. 2024;doi:10.1007/s10067-024-06991-8.…
1 Lung Cancer Edition: Top Headlines for Week of July 15, 2024 12:40
12:40 التشغيل لاحقا التشغيل لاحقا قوائم إعجاب احب12:40
التشغيل لاحقا التشغيل لاحقا قوائم إعجاب احبIn this edition, atezolizumab benefits PD-L1-selected patients with NSCLC, risks persist with e-cigarette use after quitting tobacco smoking and more. Read the full coverage here: Adjuvant atezolizumab benefits PD-L1-selected patients with NSCLC Lung cancer risks persist with e-cigarette use after quitting tobacco smoking COPD, IPF end of life health care use differs from lung cancer Tecentriq combination fails to improve survival in metastatic lung cancer Risk for lung cancer reoccurrence may be associated with OSA-related hypoxemia References: Figueroa Rodriguez F, et al. 0468: CRASH: Cancer reoccurrence is accelerated by episodic hypoxemia. Presented at: SLEEP; June 1-5, 2024; Houston. Kim Y, et al. Association of electronic cigarette use after conventional smoking cessation with lung cancer risk: A nationwide cohort study. Presented at: American Thoracic Society International Conference; May 18-22, 2024; San Diego. Press Release Suen AO, et al. Am J Respir Crit Care Med. 2024;doi:10.1154/ajrccm-conference.2024.209.1_MeetingAbstracts.A5040. Wakelee HA, et al. Abstract LBA8035. Presented at: ASCO Annual Meeting; May 31-June 4, 2024; Chicago.…
1 DME/Retina Edition: Top Headlines for Week of July 8, 2024 10:22
10:22 التشغيل لاحقا التشغيل لاحقا قوائم إعجاب احب10:22
التشغيل لاحقا التشغيل لاحقا قوائم إعجاب احبIn this edition, FDA approves Vabysmo prefilled syringe for retinal diseases, 4D Molecular Therapeutics updates on retinal disease candidates and more. Read the full coverage here: FDA approves Vabysmo prefilled syringe for retinal diseases VIDEO: 4D Molecular Therapeutics shares update on retinal disease candidates FDA approves Eylea biosimilar FYB203/Ahzantive VIDEO: Oral therapy improves central subfield thickness in DME in early-stage study ANI Pharmaceuticals to acquire Alimera Sciences References: Agrawal R. RZ402: Initial results from a phase 2 study of a novel, orally administered PKal inhibitor in patients with DME. Presented at: Clinical Trials at the Summit; June 8, 2024; Park City, Utah. Healio Interviews Press Release Press Release Press Release Editor's note: At the 1:35 mark, we mention that Vabysmo will be available later this year. This specifically applies to Vabysmo pre-filled syringe. There is a currently available formulation already on the market.…
1 Rheumatology/Psoriatic Arthritis Edition: Top Headlines for Week of June 24, 2024 10:14
10:14 التشغيل لاحقا التشغيل لاحقا قوائم إعجاب احب10:14
التشغيل لاحقا التشغيل لاحقا قوائم إعجاب احبIn this edition, extensive psoriasis and IBD history predict difficult-to-treat psoriatic arthritis, targeted therapies demonstrate low risk for serious infection and more. Read the full coverage here: Extensive psoriasis, IBD history predict difficult-to-treat psoriatic arthritis Targeted psoriatic arthritis therapies demonstrate low risk for serious infection VIDEO: Dermatologists, rheumatologists share care in psoriasis, psoriatic arthritis Patients with arthritis at higher risk for poor nutrition regardless of function FDA approves Rinvoq for JIA, psoriatic arthritis in children aged 2 years and older References: Bastard L, et al. RMD Open. 2024;doi:10.1136/rmdopen-2023-003865. Bennett R, et al. Sci Rep. 2024;doi:10.1038/s41598-024-58370-7. Husni ME. Update in the treatment of psoriatic arthritis. Presented at: Medical Dermatology Therapy Update III; May 29-31, 2024; Cleveland. Press Release Vassilakis KD, et al. Rheumatology. 2024;doi:10.1093/rheumatology/keae263.…
مرحبًا بك في مشغل أف ام!
يقوم برنامج مشغل أف أم بمسح الويب للحصول على بودكاست عالية الجودة لتستمتع بها الآن. إنه أفضل تطبيق بودكاست ويعمل على أجهزة اندرويد والأيفون والويب. قم بالتسجيل لمزامنة الاشتراكات عبر الأجهزة.
Daily Deals
Player FM - تطبيق بودكاست
انتقل إلى وضع عدم الاتصال باستخدام تطبيق Player FM !
انتقل إلى وضع عدم الاتصال باستخدام تطبيق Player FM !
))
